Flatiron Health has announced its participation in the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9 to 12 in San Antonio, Texas. The company will present multiple research studies, including three spotlight presentations and four poster sessions, highlighting the power of real-world data and analytics in advancing breast cancer care. Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health, emphasized the importance of integrated data and clinical expertise. She noted that breast cancer is the most common cancer in women globally, and understanding treatment effectiveness, biomarker-driven strategies, outcomes, and real-world access requires robust data infrastructure. “When you have the right data infrastructure, analytics, and clinical expertise working together, you can answer virtually any question about breast cancer care and outcomes,” she said. Key research highlights include: A spotlight presentation on personalized acquired resistance to CDK4/6 inhibitors, exploring links to baseline factors like obesity using real-world clinical-multiomics data. A study examining racial and ethnic disparities in access to novel therapies and outcomes among patients with triple-negative breast cancer. An investigation into real-world use of glucagon-like peptide-1 (GLP-1) therapies and their association with clinical features, social determinants, and circulating tumor DNA positivity in breast cancer patients. Research on real-world progression-free survival 2 (rwPFS2) and tumor response in patients with HR+/HER2– metastatic breast cancer treated with CDK4/6 inhibitors and aromatase inhibitors. A study on treatment patterns and outcomes in patients with ESR1-mutated ER+ metastatic breast cancer in the U.S. from 2018 to 2024. An analysis of treatment patterns in 1,954 U.S. patients with HER2-negative early breast cancer and germline BRCA mutations between 2021 and 2025. A study on overall survival with palbociclib plus an aromatase inhibitor in overweight or obese patients with HR+/HER2– metastatic breast cancer. These studies leverage Flatiron’s Panoramic Data, a comprehensive real-world data platform covering over 5 million patients across solid tumors and hematologic malignancies. The platform supports deep biomarker analysis, longitudinal tracking, and insights into high-priority patient subgroups. Flatiron Health, an independent affiliate of the Roche Group, continues to advance oncology by transforming real-world patient data into actionable insights. The company is committed to using data to improve care, accelerate research, and support smarter, more personalized cancer treatment. For more information, visit Flatiron.com and follow the company on X and LinkedIn for updates from #SABCS25.